FUSN Stock Price, Fusion Pharmaceuticals Quote, Chart

Market Summary

USD21.40-0.02

Market Closed

-0.09%

FUSN Stock Price

View Fullscreen

FUSN RSI Chart

FUSN Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-19.14

Price/Sales (Trailing)

190.65

EV/EBITDA

-20.3

Price/Free Cashflow

-21.19

FUSN Price/Sales (Trailing)

FUSN Profitability

EBT Margin

-987.93%

Return on Equity

-42.65%

Return on Assets

-33.2%

Free Cashflow Yield

-4.72%

FUSN Fundamentals

FUSN Revenue

Revenue (TTM)

9.5M

Rev. Growth (Yr)

75.23%

Rev. Growth (Qtr)

-18.67%

FUSN Earnings

Earnings (TTM)

-94.9M

Earnings Growth (Yr)

-14.47%

Earnings Growth (Qtr)

-63.34%

Breaking Down FUSN Revenue

Last 7 days

0.8%

Last 30 days

1.0%

Last 90 days

100.8%

Trailing 12 Months

478.4%

How does FUSN drawdown profile look like?

FUSN Financial Health

Current Ratio

15.01

Debt/Equity

0.16

Debt/Cashflow

-2.35

FUSN Investor Care

Shares Dilution (1Y)

34.28%

Diluted EPS (TTM)

-1.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0M	6.3M	8.5M	9.5M
2022	826.0K	1.3M	1.7M	2.2M
2021	0	0	0	381.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Fusion Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 31, 2023	rawat mohit	acquired	-	-	12,843	president & cbo
Aug 31, 2023	leamon christopher p	acquired	-	-	11,957	chief scientific officer
Nov 11, 2022	khuong chau quang	acquired	100,181	2.38	42,093	-
Aug 11, 2022	gannon steven	bought	90,132	2.03	44,400	-
Apr 27, 2022	valliant john	sold	-27,201	6.03	-4,511	chief executive officer
Apr 26, 2022	valliant john	sold	-13,032	6.07	-2,147	chief executive officer
Apr 25, 2022	valliant john	sold	-12,277	6.03	-2,036	chief executive officer
Apr 21, 2022	valliant john	sold	-5,541	6.01	-922	chief executive officer
Apr 20, 2022	valliant john	sold	-2,209	6.02	-367	chief executive officer
Apr 13, 2022	valliant john	sold	-76,881	6.41	-11,994	chief executive officer

Which funds bought or sold FUSN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	added	15.84	469,901	769,204	-%
Apr 19, 2024	Cutler Group LLC / CA	added	681	173,000	183,000	0.06%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	10,682	10,682	-%
Apr 10, 2024	Yarbrough Capital, LLC	unchanged	-	900,171	1,638,910	0.07%
Apr 05, 2024	GAMMA Investing LLC	new	-	554	554	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	new	-	290,838	290,838	-%
Feb 26, 2024	Privium Fund Management B.V.	new	-	1,173,690	1,173,690	0.33%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	19,287,300	26,440,900	0.59%
Feb 15, 2024	CHARTWELL INVESTMENT PARTNERS, LLC	new	-	480,000	480,000	0.02%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	270,349	270,349	-%

Are Funds Buying or Selling FUSN?

Are funds buying FUSN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FUSN

No. of Funds

Unveiling Fusion Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	federated hermes, inc.	11%	95,000	SC 13G/A
Mar 25, 2024	federated hermes, inc.	12.65%	10,716,153	SC 13D
Mar 20, 2024	healthcap vii, l.p.	4.5%	3,807,247	SC 13D/A
Mar 07, 2024	healthcap vii, l.p.	5.3%	3,807,247	SC 13D/A
Feb 14, 2024	canada pension plan investment board	4.%	3,116,966	SC 13G/A
Feb 13, 2024	avidity partners management lp	8.1%	6,500,328	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 19, 2024	perceptive advisors llc	6.5%	4,737,194	SC 13G
Jan 18, 2024	federated hermes, inc.	15.03%	10,886,153	SC 13G/A
Dec 18, 2023	flynn james e	8.84%	6,401,000	SC 13G

Recent SEC filings of Fusion Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	DEFA14A	DEFA14A
Apr 12, 2024	10-K/A	Annual Report
Apr 12, 2024	8-K/A	Current Report
Apr 10, 2024	PREM14A	PREM14A
Apr 09, 2024	8-K	Current Report
Apr 08, 2024	SC 13G/A	Major Ownership Report
Mar 25, 2024	SC 13D	13D - Major Acquisition
Mar 20, 2024	SC 13D/A	13D - Major Acquisition
Mar 20, 2024	10-K	Annual Report

Peers (Alternatives to Fusion Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Fusion Pharmaceuticals Inc News

Latest updates

Fusion Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2
Revenue	-18.7%	2,292,000	2,818,000	2,495,000	1,921,000	1,308,000	572,000	198,000	83,000	204,000	325,000	521,000
Operating Expenses	32.2%	28,275,000	21,395,000	26,747,000	24,883,000	24,557,000	23,971,000	19,857,000	21,110,000	18,147,000	19,840,000	27,788,000
S&GA Expenses	12.0%	7,628,000	6,810,000	7,753,000	9,006,000	6,950,000	7,420,000	7,781,000	8,449,000	6,336,000	7,156,000	6,642,000
R&D Expenses	41.6%	20,647,000	14,585,000	18,994,000	15,877,000	17,607,000	16,551,000	12,076,000	12,661,000	11,811,000	12,684,000	21,146,000
EBITDA Margin	5.4%	-9.25	-9.78	-13.45	-21.51	-40.31	-47.06	-59.40	-99.88	-210	-	-
Interest Expenses	0.5%	1,192,000	1,186,000	1,150,000	1,096,000	1,203,500	190,000	-53,000	83,000	81,000	107,000	97,000
Income Taxes	532.3%	1,297,000	-300,000	-200,000	-11,000	-329,000	-761,000	-700,000	-55,000	-173,000	48,000	14,000
Earnings Before Taxes	-	-	-	-	-	-24,957,000	-24,774,000	-19,754,000	-19,964,000	-17,409,000	-19,381,000	-26,839,000
EBT Margin	5.7%	-9.88	-10.47	-14.21	-22.37	-41.39	-47.73	-60.20	-101	-213	-	-
Net Income	-63.3%	-28,179,000	-17,252,000	-25,175,000	-24,291,000	-24,617,000	-24,013,000	-19,073,000	-19,909,000	-17,236,000	-19,429,000	-26,853,000
Net Income Margin	6.8%	-9.96	-10.69	-15.58	-23.00	-40.54	-46.75	-59.52	-101	-212	-	-
Free Cashflow	-0.6%	-19,428,000	-19,312,000	-20,294,000	-26,658,000	-20,314,000	-21,847,000	-17,691,000	-15,566,000	-16,865,000	-21,670,000	-17,516,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	12.8%	286	253	268	267	219	238	228	236	252	268	282	297	311	312	323	69.00
Current Assets	19.7%	243	203	208	221	179	216	207	205	212	203	185	234	228	297	320	67.00
Cash Equivalents	129.4%	61.00	27.00	32.00	54.00	44.00	107	63.00	61.00	55.00	40.00	30.00	43.00	92.00	251	321	67.00
Net PPE	-2.9%	5.00	5.00	6.00	5.00	5.00	4.00	4.00	3.00	3.00	2.00	3.00	3.00	2.00	2.00	1.00	1.00
Liabilities	-2.4%	63.00	65.00	65.00	66.00	57.00	55.00	29.00	21.00	21.00	22.00	19.00	18.00	16.00	6.00	8.00	10.00
Current Liabilities	-7.2%	16.00	17.00	17.00	17.00	15.00	13.00	12.00	12.00	13.00	14.00	9.00	8.00	12.00	5.00	8.00	4.00
Long Term Debt	0.4%	35.00	35.00	34.00	34.00	34.00	34.00	10.00	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.4%	35.00	35.00	34.00	34.00	34.00	34.00	10.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	18.0%	222	188	203	201	162	183	199	215	231	246	264	279	295	306	315	-
Retained Earnings	-8.1%	-376	-348	-331	-306	-281	-257	-233	-214	-194	-177	-157	-130	-113	-99.82	-89.82	-34.77
Additional Paid-In Capital	11.4%	599	538	535	507	445	442	433	430	426	423	421	410	408	406	405	1.00
Shares Outstanding	15.3%	80.00	69.00	69.00	63.00	45.00	44.00	43.00	43.00	43.00	43.00	43.00	-	-	-	-	-
Float	-	-	-	302	-	-	-	98.00	-	-	-	274	-	-	-	545	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	4.8%	-17,944	-18,839	-19,584	-25,435	-19,364	-21,625	-17,316	-14,971	-16,327	-21,510	-17,307	-20,596	-3,082	-12,868	-6,197	-7,620	-	-	-
Share Based Compensation	8.7%	3,255	2,994	3,046	3,149	2,778	2,697	2,736	2,633	2,366	2,374	2,145	1,718	1,343	1,241	426	358	-	-	-
Cashflow From Investing	-139.3%	-5,242	13,326	-26,319	-24,528	-42,933	37,248	9,641	19,131	30,896	32,217	3,659	-28,998	-155,104	-54,967	-168	-214	-	-	-
Cashflow From Financing	17538.7%	57,855	328	24,308	59,515	131	28,905	9,988	1,709	-50.00	57.00	210	130	56.00	-2,296	257,840	9,907	-	-	-

FUSN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Total revenue	$ 2,068	$ 1,461
Type of Revenue [Extensible List]	us-gaap:CollaborativeArrangementMember	us-gaap:CollaborativeArrangementMember
Operating expenses:
Research and development	$ 70,103	$ 58,895
General and administrative	31,197	30,600
Total operating expenses	101,300	89,495
Loss from operations	(99,232)	(88,034)
Other income (expense):
Interest income	9,526	2,161
Interest expense	(5,166)	(1,801)
Other income (expense), net	762	(1,775)
Total other income (expense), net	5,122	(1,415)
Loss before (provision) benefit for income taxes	(94,110)	(89,449)
Income tax (provision) benefit	(787)	1,837
Net loss	(94,897)	(87,612)
Unrealized (loss) gain on investments	706	(354)
Comprehensive loss	$ (94,191)	$ (87,966)
Net loss per share -basic	$ (1.45)	$ (2)
Net loss per share -diluted	$ (1.45)	$ (2)
Weighted-average common shares outstanding-basic	65,611,923	43,748,549
Weighted-average common shares outstanding-diluted	65,611,923	43,748,549

FUSN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 61,456	$ 43,861
Accounts receivable	7	61
Short-term investments	172,153	127,013
Prepaid expenses and other current assets	9,310	7,609
Restricted cash	469	454
Total current assets	243,395	178,998
Property and equipment, net	5,304	4,631
Deferred tax assets	3,961	4,806
Restricted cash	849	1,018
Long-term investments	13,735	15,761
Operating lease right-of-use assets	18,592	5,684
Other non-current assets		8,166
Total assets	285,836	219,064
Current liabilities:
Accounts payable	1,860	2,686
Accrued expenses and other current liabilities	9,864	10,605
Deferred revenue	333	333
Operating lease liabilities	4,163	1,443
Total current liabilities	16,220	15,067
Long-term debt, net of discount	34,775	34,233
Income taxes payable, net of current portion	301	299
Deferred revenue, net of current portion	667	2,667
Operating lease liabilities, net of current portion	11,393	4,577
Total liabilities	63,356	56,843
Commitments and contingencies (Note 15)
Shareholders’ equity:
Common shares, no par value, unlimited shares authorized as of December 31, 2023 and 2022; 79,700,262 shares and 44,805,627 shares issued and outstanding as of December 31, 2023 and 2022, respectively
Additional paid-in capital	599,002	444,552
Accumulated other comprehensive income (loss)	237	(469)
Accumulated deficit	(376,759)	(281,862)
Total shareholders' equity	222,480	162,221
Total liabilities and shareholders’ equity	$ 285,836	$ 219,064

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

CEO	Dr. John F. Valliant Ph.D.
WEBSITE	https://fusionpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	101

Fusion Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Fusion Pharmaceuticals Inc? What does FUSN stand for in stocks?

FUSN is the stock ticker symbol of Fusion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fusion Pharmaceuticals Inc (FUSN)?

As of Wed Apr 24 2024, market cap of Fusion Pharmaceuticals Inc is 1.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers.

What is the fair value of FUSN stock?

You can check FUSN's fair value in chart for subscribers. The fair value of Fusion Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fusion Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FUSN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fusion Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FUSN is over valued or under valued. Whether Fusion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fusion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FUSN.

What is Fusion Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, FUSN's PE ratio (Price to Earnings) is -19.14 and Price to Sales (PS) ratio is 190.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FUSN PE ratio will change depending on the future growth rate expectations of investors.